What do systematic reviews say?

Neoadjuvant treatment vs no neoadjuvant treatment

It is very uncertain whether neoadjuvant treatment changes overall survival (OS), measured by the number of deaths over time… compared with no neoadjuvant treatment (very low certainty).

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  HR 0.43 [0.15, 1.21]
  2 studies · 171 participants
  Very low

Neoadjuvant targeted treatment (BRAF/MEK inhibition) vs no neoadjuvant treatment

It is very uncertain whether neoadjuvant targeted treatment (BRAF/MEK inhibition) changes overall survival (OS), measured by number of deaths over time,Median compared with no neoadjuvant treatment (very low certainty).

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  HR 0.28 [0.03, 2.25]
  1 study · 21 participants
  Very low

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (sequential treatment with ipilimumab then nivolumab)

The review found no eligible studies for this question.

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Neoadjuvant immunotherapy (talimogene laherparepvec) vs no neoadjuvant treatment

It is very uncertain whether neoadjuvant immunotherapy (talimogene laherparepvec) changes overall survival (OS), measured by the number of deaths over time, compared with no neoadjuvant treatment (very low certainty).

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  HR 0.49 [0.15, 1.64]
  1 study · 150 participants
  Very low

Neoadjuvant immunotherapy (high dose interferon) plus chemotherapy vs neoadjuvant chemotherapy

The review found no eligible studies for this question.

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs neoadjuvant immunotherapy (nivolumab)

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 23 participants
  Moderate

Neoadjuvant chemotherapy prior to interval surgery (NACT) vs surgery followed by chemotherapy (PDS)

Neoadjuvant chemotherapy prior to interval surgery (NACT) showed no clear difference in overall survival ( compared with surgery followed by chemotherapy (PDS) (high certainty).

• Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced… 2021 · Cochrane Headline outcomes only
  HR 0.96 [0.86, 1.08]
  4 studies · 2000 participants
  High

Neoadjuvant immunotherapy (combined ipilimumab and nivolumab) vs adjuvant immunotherapy (combined ipilimumab and nivolumab)

The review found no eligible studies for this question.

• Neoadjuvant treatment for stage III and IV cutaneous melanoma 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Capecitabine‐containing regimens vs chemotherapy regimens without capecitabine

Capecitabine‐containing regimens showed no clear difference in overall survivalmedian compared with non‐capecitabine‐containing regimens (high certainty).

• Capecitabine for hormone receptor‐positive versus hormone receptor‐negative breast cancer 2021 · Cochrane Headline outcomes only
  HR 0.97 [0.77, 1.23]
  4 studies · 2499 participants
  High

Physical activity vs usual care

The review found no eligible studies for this question.

• Physical activity interventions for disease‐related physical and mental health during and following treatment in… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found